NCT03917043 - APG-2449 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

January 31, 2028

Conditions

Advanced Solid CancerNon Small Cell Lung CancerEsophageal CancerOvarian CancerMalignant Pleural Mesothelioma

Interventions

DRUG

APG-2449

Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle

Trial Locations (9)

RECRUITING

Beijing Cancer Hospital, Beijing

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Sun-Yat Sen University Cancer Center, Guangzhou

RECRUITING

The First affiliated hospital, Sun Yat-sen University, Guangzhou

RECRUITING

Henan Provincial Oncology Hospital, Zhengzhou

RECRUITING

Union Hospital medical college Huazhong University of Science and Technology, Wuhan

RECRUITING

Hunan Provincial Oncology Hospital, Changsha

RECRUITING

Zhejiang Provincial Oncology Hospital, Hangzhou